Lilly reports positive one-year Phase 3 results for Omvoh in pediatric ulcerative colitis

Eli Lilly said it has achieved positive one-year results from a late-breaking Phase 3 study testing Omvoh (mirikizumab-mrkz) in pediatric ulcerative colitis, a form of inflammatory bowel disease that can cause persistent diarrhea, abdominal pain, and bleeding. In a new update tied to the SHINE-2 program, Lilly reported that the trial met its primary endpoint of clinical remission in children and adolescents ages 6 to 17 with moderately to severely active disease.

The announcement focuses on the one-year data from SHINE-2, which Lilly described as evaluating Omvoh in a pediatric population. Omvoh targets IL-23p19, a protein involved in immune indicating that contributes to inflammatory activity in certain autoimmune and inflammatory conditions. By blocking IL-23p19, the therapy is intended to reduce inflammation that drives ulcerative colitis symptoms.

Lilly also framed the results as a first-of-its-kind milestone for the class, saying Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis. That claim, if sustained through regulatory and scientific review, could influence how clinicians and payers compare treatment timelines and durability of response across biologic therapies used in younger patients.

The company’s update was carried by Yahoo Finance on Oct. 19, 2026, and characterized the findings as meeting the study’s primary endpoint. The report did not provide detailed statistics in the text available here, including the exact remission rates at one year, the breakdown by subgroup, or the magnitude of improvement versus placebo or background therapy.

Because the disclosed excerpt does not include safety and tolerability tables, it is not possible to determine from the available information how adverse events compared between treatment and control arms, or whether any indicates emerged over the one-year period. Lilly also did not specify whether the trial’s primary endpoint used a particular ulcerative colitis scoring system or defined remission using endoscopic, symptom-based, or combined criteria in the excerpt provided.

In broader terms, pediatric ulcerative colitis has been an area of intense development for immune-modulating biologics, reflecting the difficulty of managing a chronic condition that can affect growth, school attendance, and quality of life. For drug makers, pediatric Phase 3 results can be especially consequential because they can inform label expansion plans and future competition in earlier lines of therapy.

Still, the pathway from clinical results to a change in clinical practice depends on what Lilly submits to regulators, including the full dataset, statistical analysis, and safety follow-up. The market often treats late-breaking trial updates as an early announcement of potential regulatory strength, but definitive conclusions usually come after complete disclosures and regulatory review.

For investors and clinicians, the next step to watch is whether Lilly provides more granular trial data and timelines for any regulatory filings tied to SHINE-2, and whether the one-year efficacy profile holds alongside longer follow-up. Additional details on durability, remission depth, and safety will likely determine how the results are interpreted in the context of other pediatric ulcerative colitis therapies.